Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: An (R)-[11 C]verapamil PET study

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 5, 2015, Pages 743-746

  Bauer, Martin ^a   Karch, Rudolf ^a   Zeitlinger, Markus ^a   Philippe, Cécile ^a   Römermann, Kerstin ^a,b   Stanek, Johann ^a,c   Maier Salamon, Alexandra ^d   Wadsak, Wolfgang ^a   Jäger, Walter ^d   Hacker, Marcus ^a   Müller, Markus ^a   Langer, Oliver ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^c AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

(R) 11C verapamil; blood brain barrier; P glycoprotein; pituitary gland; positron emission tomography; tariquidar

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; RADIOPHARMACEUTICAL AGENT; TARIQUIDAR; UNCLASSIFIED DRUG; VERAPAMIL C 11; ABCB1 PROTEIN, HUMAN; ANTIARRHYTHMIC AGENT; CARBON; VERAPAMIL;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG UPTAKE; EC50; GRAY MATTER; HUMAN; HUMAN EXPERIMENT; HYPOPHYSIS; MALE; NEUROIMAGING; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; RADIOGRAPHY;

ANTI-ARRHYTHMIA AGENTS; BLOOD-BRAIN BARRIER; CARBON ISOTOPES; GRAY MATTER; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEINS; PITUITARY GLAND; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; VERAPAMIL;

EID: 84928826038     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.19     Document Type: Article

References (16)

1. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, et al. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 2013; 94: 80-94
2. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502
3. Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Müller M, Langer O, et al. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Clin Pharmacol Ther 2014; 96: 206-213
4. Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, et al. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human bloodbrain barrier with (R)-11C-verapamil and PET. J Nucl Med 2009; 50: 1954-1961
5. Muzi M, Mankoff DA, Link JM, Shoner S, Collier AC, Sasongko L, et al. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med 2009; 50: 1267-1275
6. Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, et al. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med 2010; 51: 559-566
7. Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jäger W, et al. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther 2012; 91: 227-233
8. Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, et al. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[11C]verapamil. Epilepsia 2007; 48: 1774-1784
9. Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, Stundner G, et al. Doseresponse assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C] verapamil PET. Eur J Nucl Med Mol Imaging 2010; 37: 942-953
10. Kreisl WC, Bhatia R, Morse CL, Woock AE, Zoghbi SS, Shetty HU, et al. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar. J Nucl Med 2015; 56: 82-87
11. Ke AB, Eyal S, Chung FS, Link JM, Mankoff DA, Muzi M, et al. Modeling cyclosporine A inhibition of the distribution of a p-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition. J Nucl Med 2013; 54: 437-446
12. Seyama S, Pearl GS, Takei Y. Ultrastructural study of the human neurohypophysis. III. Vascular and perivascular structures. Cell Tissue Res 1980; 206: 291-302
13. Eyal S, Ke B, Muzi M, Link JM, Mankoff DA, Collier AC, et al. Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther 2010; 87: 579-585
14. Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, et al. Interaction of 11C-Tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J Nucl Med 2013; 54: 1181-1187
15. Sugimoto H, Hirabayashi H, Amano N, Moriwaki T. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans. Drug Metabol Dispos 2013; 41: 683-688
16. Zhang K, Herzog H, Mauler J, Filss C, Okell TW, Kops ER, et al. Comparison of cerebral blood flow acquired by simultaneous [15O]water positron emission tomography and arterial spin labeling magnetic resonance imaging. J Cereb Blood Flow Metab 2014; 34: 1373-1380